Is there a path forward for mGlu(2) positive allosteric modulators for the treatment of schizophrenia?
about
Group II Metabotropic Glutamate Receptors as Targets for Novel Antipsychotic DrugsPositive allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatmentPerspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end?The NMDA Receptor and Schizophrenia: From Pathophysiology to Treatment.A short-term, multicenter, placebo-controlled, randomized withdrawal study of a metabotropic glutamate 2/3 receptor agonist using an electronic patient-reported outcome device in patients with schizophrenia.Development of allosteric modulators of GPCRs for treatment of CNS disordersOpportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders.The antipsychotic-like effects in rodents of the positive allosteric modulator Lu AF21934 involve 5-HT1A receptor signaling: mechanistic studies.Allosteric Binding Site and Activation Mechanism of Class C G-Protein Coupled Receptors: Metabotropic Glutamate Receptor Family.Computational Advances for the Development of Allosteric Modulators and Bitopic Ligands in G Protein-Coupled ReceptorsThe Emerging Role of Metabotropic Glutamate Receptors in the Pathophysiology of Chronic Stress-Related DisordersPractical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate ReceptorsAllosteric Modulation of GPCRs: New Insights and Potential Utility for Treatment of Schizophrenia and Other CNS Disorders.
P2860
Q26744729-6B898C6A-5B91-4FA0-BB0D-C296390F4040Q26852047-1321AF43-0C61-47C5-8F04-54BDC68DAC0FQ30379983-71B10102-B693-4D8B-9759-5EE3F23B8A24Q33920257-A627A38A-AE0B-48F3-AE13-2360D1BD0A98Q34194022-2F246304-4551-414B-AE64-67DBD06E20B9Q34373958-3F11BBFD-4F23-40F1-B010-88CC5074D4F7Q34399823-4E1D5104-C61C-47E0-BDB4-B334D1A2022FQ34798345-57107926-99BF-4525-BAC7-AE2147AF2D00Q35529175-64237408-19D5-4A6A-99DF-46B047C7D958Q35967903-30DCF7B5-F437-4B49-BFE4-F2636AF3F041Q37172873-5C946431-9B8F-4EFA-8BDD-B8047A55CEC9Q37183072-DF2C5AD3-FB01-41B2-A76D-DC4CB6B9CA70Q39284158-574D45EA-100D-48F0-BB70-B4D469A2E6DC
P2860
Is there a path forward for mGlu(2) positive allosteric modulators for the treatment of schizophrenia?
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Is there a path forward for mG ...... he treatment of schizophrenia?
@en
type
label
Is there a path forward for mG ...... he treatment of schizophrenia?
@en
prefLabel
Is there a path forward for mG ...... he treatment of schizophrenia?
@en
P2860
P356
P1476
Is there a path forward for mG ...... he treatment of schizophrenia?
@en
P2860
P304
P356
10.1021/CN400023Y
P577
2013-02-01T00:00:00Z